Skip to content

Trastuzumab

Herceptin (trastuzumab) is an antibody pharmaceutical. Trastuzumab was first approved as Herceptin on 1998-09-25. It is used to treat breast neoplasms and gastrointestinal neoplasms in the USA. It has been approved in Europe to treat breast neoplasms and stomach neoplasms. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2.
Trade Name Herceptin
Common Name Trastuzumab
ChEMBL ID CHEMBL1201585
Indication breast neoplasms, gastrointestinal neoplasms, stomach neoplasms
Drug Class Monoclonal antibodies: humanized, tumors as target
Trastuzumab
Get full access now